Citations

Clear

62 citation(s) found for "Madsen, Bo".

Amyloid‐Related Imaging Abnormalities Summit Special Proceedings: Cardiovascular and Stroke Considerations for β‐Amyloid Immunotherapy in Alzheimer Disease
Greenberg, Steven M. , Iadecola, Costantino , Chou, Sherry , Cogswell, Petrice M, Elkind, Mitchell S.V. , II, William J. Hicks, Le, Caitlin, Levine, Deborah A. , Lipton, Richard B. , Massimo, Lauren, Mohl, Stephanie M. , Snyder, Heather M. , Yaffe, Kristine , Adams, Robert, Agronin, Marc, Atri, Alireza, Bauman, Mary Ann, Bernat, James L., Biffi, Alessandro , Blum, Sonja, Bussiere, Thierry, Carrillo, Maria C., Chiang, Gloria, Cato, Kenrick, Chaitoff, Alexander, Bakken, Suzanne, Schelke, Matthew W. , Cruz‐Flores, Salvador, Derdeyn, Colin, Dhand, Amar, Evans, David A., Gettel, Cameron, Goldstein, Larry B, Grill, Joshua, Kulshrestha, Ambar, Lam, Christine, Lazar, Ronald M. , Li, Hanlin , Madsen, Tracy, Ramanan, Vijay K., McCullough, Louise, Merino, José G., Orjuela, Karen, Guo, Michael, Messe, Steve, Tubiello, Maggie, Ruff, Christian T., Selim, Magdy, Sha, Sharon J., Sheth, Kevin, Stamm, Brian, Buckwalter, Marion, Skylar-Scott, Irina, Lavretsky, Helen, Saver, Jeffrey, Rabinovici, Gil D., VandeVrede, Lawren, Goyal, Manu S., Weisman, David C., Lipton, R.B. , Chou, Sherry H-Y , Seshadri, Sudha , Snyder, Heather M , Yaffe, Kristine , Zachrison, Kori S , Cogswell, Petrice M. , Hicks, William J., Massimo, Lauren , Seshadri, Sudha , Atri, Alireza, Blum, Sonja, Bussière, Thierry , Carlisle, Tara C. , Chaitoff, Alexander , Cruz-Flores, Salvador, Chyou, Janice Y. , Derdeyn, Colin P. , Gettel, Cameron J. , Goldstein, Larry B. , Grill, Joshua D. , Ishii, Makoto , Kulshreshtha, Ambar , Rabinstein, Alejandro A. , Ramanan, Vijay K. , McCullough, Louise D. , Merino, José G. , Messé, Steven R. , Ruff, Christian Thomas , Saklad, Stephen R. , Selim, Magdy H. , Shah, Sachin J. , Stamm, Brian , Buckwalter, Marion S. , Skylar-Scott, Irina A., Rabinovici, Gil D. , VandeVrede, Lawren , Chatterjee, Arindam R , Wunderink, Richard G.

Mayo Clinic

Journal of the American Heart Association | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/jaha.125.048108 | PMID 42622140 Get It

Background New antiamyloid therapies (AAT) for treating patients with early Alzheimer disease (AD) have become available in the past 3 years. Although AAT can be beneficial in slowing progression of AD, they also come with potentially serious side effects, particularly for patients requiring anticoagulation or thrombolysis for cardiovascular conditions. Given that most patients with AD are older and likely to have cardiovascular risk factors, there is urgent need for additional guidance for clinicians about potential risks and benefits associated with AAT for patients with cardiovascular comorbidities, best practices for management of these patients, and special considerations with respect to emergency evaluation and treatment of patients on AAT who develop acute neurological symptoms. Methods The American Heart Association convened 75 multidisciplinary experts for the Amyloid‐Related Imaging Abnormalities Summit: Cardiovascular and Stroke Considerations for β‐Amyloid Immunotherapy in AD in July 2025. These experts were divided into 8 work groups to evaluate the current evidence related to AAT usage in patients with cardiovascular risk factors and conditions and develop consensus‐based guidance for clinicians. Results This statement outlines the outcomes of the Summit, including considerations for prescribers, primary care professionals, emergency personnel, and health care system stakeholders. These considerations are intended to improve identification of patients as appropriate candidates for AAT, management of patients with co‐occurring AD and cardiovascular conditions, and their emergency evaluation and treatment. The statement also includes guidance for shared decision‐making, implementation of system changes for improving dementia care, and recommendations for future research and data collection to add to the body of evidence for treating patients with concomitant AD and cardiovascular conditions. Conclusions Building on lessons learned from the establishment of stroke systems of care, the consensus‐based considerations outlined in this document can serve as a foundation for AD systems of care aimed at ensuring optimal use of these ground‐breaking therapies.
Long‐Term Outcomes After Retropubic and Transobturator Sling Procedures: Reoperation for Recurrent Stress Urinary Incontinence
Trad, Ayssa Teles Abrão , Nashar, Sherif A. El, Madsen, Annetta M., Occhino, John A. , Gebhart, John B. , McGree, Michaela E. , Fought, Angela J. , Trabuco, Emanuel C. , El Nashar, Sherif A, Linder, Brian J , El‐Nashar, Sherif A. , Linder, Brian J. , Madsen, Annetta M.

Mayo Clinic

BJOG: An International Journal of Obstetrics & Gynaecology | July 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/1471-0528.70295 | PMID 42392760 Get It

ABSTRACT Objective To evaluate long‐term failure rates and complications after retropubic and transobturator midurethral sling procedures for primary stress urinary incontinence (SUI). Design Retrospective cohort study. Setting Academic medical centre. Population A previously described cohort of patients ( n = 1881) who underwent midurethral sling procedures (2002–2012) and a covariate‐matched cohort of patients with retropubic ( n = 570) or transobturator ( n = 317) slings. Methods Health record review with follow‐up extended by 9 years (through December 31, 2022). Main Outcome Measures Treatment failure (reoperation for recurrent SUI) and procedure‐associated complications. Results The duration of assessment was extended by 6.9 years for the retropubic group and by 6.4 years for the transobturator group. The median (IQR) follow‐up was 11.1 (5.1–14.5) years (retropubic, 11.4 [5.9–14.6]; transobturator, 9.6 [2.6–13.7]). Higher risk of reoperation was observed with transobturator (8.8%) than retropubic (4.4%) slings (unadjusted hazard ratio [HR], 2.29 [95% CI, 1.49–3.54]; p < 0.001; covariate‐matched analysis HR, 1.91 [95% CI, 1.15–3.17]; p = 0.01). The increased risk of reoperation with a transobturator sling was higher when the procedure was combined with prolapse repair (unadjusted HR, 6.34 [95% CI, 3.09–13.02]; p < 0.001; covariate‐matched analysis HR, 3.96 [95% CI, 1.35–11.58]; p = 0.01). Higher rates of reoperation for urinary retention were observed for the retropubic group than for the transobturator group (covariate‐matched analysis HR, 8.39 [95% CI, 1.11–63.22]; p = 0.04). Conclusion In this long‐term follow‐up study, midurethral slings had a low failure rate. Women with SUI undergoing transobturator sling placement plus prolapse repair had a greater risk of reoperation. However, women with retropubic slings had a greater risk of urinary retention requiring intervention.
Factors associated with aortic valve calcification in type 2 diabetes—a Steno INTEN-CT substudy
Haujir, Amal , Kumarathurai, Preman , Stidsen, Jacob V. , Funck, Kristian Løkke , Mohammad, Batool J Y, Ravn, Emil Johannes , Engelsgaard, Camilla, Ramanathan, Ramshanker , Madsen, Lene Helleskov, Hansen, Monija Mrgan, Böttcher, Morten, Pietraszek, Anna , Olsen, M, Karon, Marek , Hansen, Tine W. , Eskesen, Kristian , Calderon, Elena , Lambrechtsen, Jess , Øvrehus, Kristian Altern , Diederichsen, Axel CP, Dahl, Jordi S, Diederichsen, Axel Cosmus Pyndt , Funck, Kristian Løkke , Ravn, Emil Johannes , Kofoed, Klaus Fuglsang , Karon, Marek , Lambrechtsen, Jess , Clavel, Marie-Annick , Diederichsen, Axel , Haujir, Amal , Poulsen, Per Løgstrup , Mohammad, Batool J.Y., Hasific, Selma , Engelsgaard, Camilla Skals , Bøttcher, Morten , Olsen, Michael Hecht , Clavel, Marie‐Annick , Dahl, Jordi S.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | June 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ehjci/jeag139 | PMID 42290203 Get It

Abstract Aims This study aimed to identify clinical factors associated with AVC in individuals with T2D. Methods and results This cross-sectional study is a pre-specified substudy of the multicentre randomized Steno INTEN-CT trial (Clinical Trials—INTEN-CT). Participants were eligible if they had T2D without ischaemic heart disease and were aged between 55–69 years (men) or 60–74 years (women). All participants underwent non-contrast cardiac computed tomography. AVC was measured in Agatston Units and categorized as 0, 0–300, ≥ 300. Of the 4570 participants, 46% had AVC &gt; 0. With increasing AVC, patients were older, predominantly males, and with significantly more comorbidities. In multivariable ordered logistic regression age (OR per SD 1.54, 95% CI 1.43–1.66), BMI (OR per SD 1.18, 95% CI 1.11–1.25), hypertension (OR 1.21, 95% CI 1.05–1.40), and chronic kidney disease (OR 1.18, 95% CI 1.03–1.36) were associated with higher AVC. Statin use was also associated with higher AVC (OR 1.50, 95% CI 1.27–1.78). Higher LDL cholesterol showed stronger associations with AVC in men than women (OR 1.39, 95% CI 1.24–1.56 vs. OR 1.16, 95% CI 1.02–1.31, P for interaction = 0.025). T2D severity (Haemoglobin A1c, T2D duration, and number of antidiabetic drugs) was not associated with AVC. Conclusion In individuals with T2D without cardiovascular disease, AVC is prevalent in nearly half of all individuals. Higher AVC was associated with T2D-related comorbidities, but not T2D severity.
Midodrine for Sepsis Treatment and Early Vasopressor Weaning (MID-STEP): protocol for a pragmatic randomised clinical trial
Tekin, Aysun , Halpern, Gabriele, Gowda, Diksha , Bansal, Vikas , Schuchard, Amy, Schulte, Phillip, Odeyemi, Yewande , Ahmad, Sumera, Madsen, Bo, Rizwan, Zeeshan, Frazee, Erin N. , Reddy, Swetha , Bhavsar, Vatsa, Sanghavi, Devang, Garces, Juan Pablo Domecq , Khan, Syed Anjum , Cartin-Ceba, Rodrigo, Gajic, Ognjen, Odeyemi, Yewande E , Domecq Garces, Juan Pablo, Lal, Amos , Tekin, Aysun , Rizwan, Zeeshan M , Halpern, Gabriele Alves, Bansal, Vikas, Jogunčić, Anes , Shiari, Aryan , Cartin‐Ceba, Rodrigo , Gajic, Ognjen , Lal, Amos

Mayo Clinic

BMJ Open | April 22, 2026 | Volume: 16 | Issue: 4 | Pages: e117846

10.1136/bmjopen-2026-117846 | PMID 42020133 Get It

Introduction Sepsis is a global health priority with nearly 50 million cases annually. Cardiovascular dysfunction is common, frequently manifesting as hypotension that persists despite fluid resuscitation. Most affected patients require the use of intravenous (IV) vasoactive agents, typically necessitating intensive care unit (ICU)-level monitoring, invasive interventions and contributing substantially to healthcare costs. Midodrine, an oral alpha-1 agonist approved for orthostatic hypotension, has increasingly been used off-label as a vasopressor-sparing (reducing IV vasopressor use) strategy in sepsis, despite limited and inconsistent evidence. This pragmatic, randomised, open-label trial evaluates the efficacy and safety of midodrine in patients with sepsis-associated hypotension. We hypothesise that, compared with standard care, midodrine administration will reduce the duration of IV vasopressor use. Methods and analysis A total of 308 adult patients with sepsis-associated hypotension will be enrolled (154 per arm). The intervention group will, in addition to standard of care, receive enteral midodrine 10 mg three times daily. Outcomes will be ascertained pragmatically via electronic health record-based data retrieval and adjudicated by research coordinators blinded to treatment assignment. The primary outcome is time alive and off IV vasopressors in the first 28 days (in hours) after randomisation. Secondary outcomes include cumulative vasopressor exposure; use and duration of central venous access; cumulative fluid balance over the first 48 hours and up to 7 days of ICU stay; ICU and hospital length of stay; and ICU-, hospital-, and organ support-free days through day 28. Safety outcomes include adverse events potentially attributable to midodrine during hospitalisation including acute kidney injury. Primary analyses will follow an intention-to-treat framework, including all randomised participants according to their assigned treatment groups. Primary and secondary outcomes will be compared using a van Elteren test stratified by randomisation factors. A predefined secondary Bayesian analysis of the primary outcome will provide complementary estimates of treatment effect. Safety outcomes will be summarised descriptively without formal between-arm hypothesis testing. Ethics and dissemination The Mayo Clinic Institutional Review Board approved this protocol and required written informed consent from all participants (IRB# 24–0 00 121). Findings will be disseminated through peer-reviewed publications and international conference presentations. Trial registration number NCT06319248 .
Family History and Solar Insolation in Bipolar I Disorder
Bauer, M., Glenn, Tasha , Achtyes, E. D., Alda, M., Ağaoğlu, Esen , Altınbaş, Kürşat , Andreassen, O. A., Angelopoulos, E., Ardau, R., Aydin, Mehmet Zeki , Ayhan, Y., Baethge, Christopher , Bauer, Rita, Baune, B. T., Balaban, Ceylan, Becerra‐Palars, Claudia, Behere, A. P., Belete, Habte , Belete, Tilahun, Belizario, G. Okawa, Bellivier, F., Belmaker, R. H., Benedetti, F., Berk, M., Bersudsky, Y., Bicakci, Ş., Birabwa‐Oketcho, Harriet , Bjella, T. D., Brady, Conan , Cabrera, Jorge , Cappucciati, Marco , Castro, A. M. Paredes, Chen, W., Cheung, E. Y. W., Chiesa, S., Chanopoulou, Margarita, Cuomo, A., Dodd, S., Etain, B., Fagiolini, A., Fellendorf, F. T., Ferensztajn‐Rochowiak, Ewa , Fiedorowicz, J. G., Fountoulakis, K. N., Frye, M. A., Geoffroy, P. A., Gitlin, M. J., Gottlieb, J. F., Grof, Paul , Haarman, B.C.M., Harima, Hirohiko, Hasse‐Sousa, M., Henry, C., Hoffding, L., Houenou, J., Imbesi, M., Isometsä, E. T., Janno, Sven , Johnsen, S., Karakatsoulis, G. N., Kardell, Mathias, Kessing, L. V., Kim, S. J., Kot, T. L., Koval, M., Lafer, B., Landén, M., Larsen, E. R., Licht, R. W., Ludwig, V. M., Mackenzie, Alan, Madsen, H. Østergaard, Madsen, S. Alberte Kongstad A., Mahadevan, J., Mahardika, Agustine , Mahfoudh, K. Ben, Manchia, M., Marsh, W., Martiny, Klaus , Mashima, Y., McLoughlin, D. M., Meesters, A. N. R., Meesters, Ybe , Melle, I., Meza‐Urzúa, F., Michaelis, Elisabeth, Mok, Y. Ming, Monteith, Scott , Moorthy, Muthukumaran, Morken, G., Mosca, Enrica, Mozzhegorov, A. A., Munoz, R., Mythri, S. V., Nadella, R. K., Nakanotani, Takako, Nielsen, R. Ernst, O'Donovan, C., Omrani, Adel, Osher, Yamima , Pantovic‐Stefanovic, M., Pariwatcharakul, Pornjira, Petite, Joanne, Pilhatsch, M., Ruiz, Y. Pica, Pinna, M., Pompili, M., Porter, R., Quiroz, Danilo , Rabelo‐da‐Ponte, F. Diego, Ramesar, Raj , Rasgon, NL, Redahan, Maria, Reddy, M. S., Reif, A., Reininghaus, E. Z., Richards, J. Gringer, Rybakowski, J. K., Sathyaputri, Leela, Scippa, A. M., Simhandl, Christian , Smith, D., Smith, J., Stackhouse, P. W., Stein, D. J., Stilwell, Kellen, Su, K.‐P., Sulaiman, A. Hatim, Suominen, Kirsi, Tanra, A. J., Tatebayashi, Yoshitaka , Teh, W. Lin, Tondo, L., Torrent, C., Tuinstra, Daniel, Uchida, Takahito, Vaaler, A. E., Vieta, E., Viswanath, B., Volf, C., Yang, K‐J, Yalcinkaya, O. Kaan, Young, A. H., Zgueb, Yosra , Whybrow, P. C., Houenou, Josselin , Isometsä, Erkki , Licht, Rasmus Wentzer , Manchia, Mirko , Nielsen, René Ernst , Stein, Dan J. , Kessing, Lars Vedel , Young, Allan H. , Achtyes, Eric D. , Belete, T , Berk, Michael , Crowe, M , Fagiolini, Andrea , Frye, Mark , Grof, P , Kessing, L V , Kim, S J , Manchia, Mirko , McLoughlin, D M , Nadella, R K , Ouali, U , Pariwatcharakul, P , Pompili, M , Porter, R , Ritter, P , Rybakowski, Janusz K , Stein, Dan J , Strejilevich, S , Subramaniam, M , Vaaler, A E , Vieta, E , Yoldi-Negrete, M , Young, Allan H , Bauer, M., Alda, Martin , Altınbaş, Kürşat , Andreassen, Ole A. , Angelopoulos, Elias, Ardau, Raffaella , Aydin, M., Ayhan, Yavuz , Behere, Aniruddh Prakash, Belizário, Gabriel Okawa , Bellivier, Frank , Belmaker, Robert H. , Benedetti, Francesco , Berk, Michael , Bıçakcı, Şule , Bjella, Thomas , Castro, Angela Marianne Paredes , Cuomo, Alessandro, Dallaspezia, Sara , Desai, Pratikkumar Vrajeshbhai , Dodd, Seetal , Étain, Bruno , Fagiolini, Andrea , Fellendorf, F.T., Fiedorowicz, Jess G. , Fountoulakis, Konstantinos Ν. , Frye, Mark A. , Geoffroy, Pierre A. , Gitlin, Michael , González‐Pinto, Ana , Haarman, Bartholomeus C. M. , Hasse-Sousa, Mathias , Henry, Chantal , Høffding, Lone, Imbesi, Massimiliano, Ivković, Maja , Johnsen, Søren Paaske , Kapczinski, Flávio , Karakatsoulis, Grigorios N. , König, Barbara , Kunz, Maurício , Lafer, Beny , Landén, Mikael , Ludwig, Vera Miriam , López‐Jaramillo, Carlos , MacKenzie, A., Madsen, Helle Østergaard , Mahfoudh, K., Marsh, W., Martínez‐Cengotitabengoa, Mónica , Martini, Julia , Mashima, Yuki , Meesters, Alie N.R., Melle, Ingrid , Meza-Urzúa, Fátima, Mikoláš, Pavol , Mok, Yee Ming , Morken, Gunnar , Mozzhegorov, Anton A., Mythri, SV, C, O'Donovan, Ouali, Uta , Stefanovic, M. Pantovic, Pfennig, Andrea , Ruiz, Yolanda Pica, Pinna, Marco , Rabelo-Da-Ponte, F.D., Rasgon, Natalie , Ratta‐apha, Woraphat , Redahan, Maria, Reif, A., Reininghaus, EZ, Ritter, Philipp , Strejilevich, Sergio , Suominen, Kirsi, Teh, Wen Lin , Torrent, C., Vieta, Eduard , Viswanath, Biju , Yoldi‐Negrete, María , Young, A.H., Whybrow, Peter C.

Mayo Clinic

Acta Psychiatrica Scandinavica | March 8, 2026 | Volume: 153 | Issue: 4 | Pages: 270-278

10.1111/acps.70075 | PMID 41734899 Get It

ABSTRACT Background Sunlight has profound impacts on physical and mental health, beyond vision, including effects on circadian rhythms, alertness, mood, and sleep. A family history of any mood disorders is strongly associated with psychiatric disorders including bipolar disorder. The purpose of this study was to evaluate the association between a family history of any mood disorder in patients with bipolar I disorder and solar insolation at varied international onset locations. Methods Data for this analysis were available from 5842 patients with a diagnosis of bipolar I disorder obtained at 83 collection sites in both hemispheres. This included 4752 patients from 71 collection sites in the northern hemisphere and 1090 patients from 12 collection sites in the southern hemisphere. Patient data variables were obtained from records or interviews. Solar insolation data were obtained from The National Aeronautics and Space Administration (NASA) Power database for each onset location, and the ratio of the mean monthly minimum/mean monthly maximum solar insolation was calculated. Typically, the ratio is largest near the equator (little yearly change in solar insolation) and smallest near the poles (large yearly change in solar insolation). Results A significant relationship was found between a family history of any mood disorder, the ratio of the mean monthly minimum/mean monthly maximum solar insolation, and gender. The odds of a family history of mood disorder increased as patient location nears the poles and decreased near the equator. Female gender also increased the odds of having a family history of a mood disorder. Conclusions This study highlighted the association between family history, solar insolation, and gender in international patients with bipolar I disorder. Given the profound effects of sunlight on human health, the family of patients with bipolar disorder who live in the same location with the same solar insolation, and especially females, may be at increased risk for a mood disorder.
Rucaparib vs docetaxel (DTX) or second-generation androgen receptor pathway inhibitor (ARPI) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutations based on
Fizazi, Karim , Chowdhury, Simon, Ryan, Charles J. , Villanueva, Noemí, Caffo, O., Chakmakjian, Carl, Ernst, D. Scott, Feyerabend, Susan , Font, Albert , Ganju, Vinod, Kushnir, Igal , MADSEN, CHRISTINE VESTERGAARD, Borrow, Jen, Ong, Valerie Shu Fei., Ostler, Peter , Reaume, Martin Neil , Bryce, Alan H. , Villanueva, Noemi , Caffo, Orazio , Ernst, D. Scott, Ganju, Vinod, Hajdenberg, Julio J.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 46-46

10.1200/jco.2026.44.7_suppl.46 Get It

46 Background: Primary results from the randomized, multicenter, open-label, phase 3 TRITON3 (NCT02975934) study demonstrated that rucaparib significantly improved radiographic progression-free survival (rPFS) vs physician’s choice of DTX or an ARPI. ECOG PS is used as a predictor of prostate cancer survival. In this post hoc analysis, we report results from the BRCA1/2 subgroup of pts stratified by ECOG PS. Methods: Pts with disease progression after 1 prior second-generation ARPI in any setting were randomized 2:1 to rucaparib 600 mg BID or physician’s choice of DTX or ARPI (abiraterone acetate or enzalutamide). Primary endpoint was rPFS by independent radiology review (IRR). Objective response rate (ORR) for pts with measurable disease and overall survival (OS) were key secondary endpoints. Crossover from physician’s choice to rucaparib was allowed after radiographic progression was confirmed by IRR. Data cutoff was August 25, 2022. Results: Of 302 pts in the BRCA1/2 population, 147 had an ECOG status of 0 (97 rucaparib; 50 physician’s choice) and 155 had ECOG 1 (104 rucaparib; 51 physician’s choice). Baseline characteristics and demographics were generally similar between arms for pts in the ECOG 0 and ECOG 1 groups. Median rPFS favored rucaparib vs physician’s choice for pts with ECOG 0 (11.4 vs 8.2 months; HR, 0.48 [95% CI, 0.30-0.76]) and ECOG 1 (10.9 vs 6.1 months; HR, 0.48 [95% CI, 0.31-0.74]) (Table). Additionally, rPFS favored rucaparib for ECOG 0 and ECOG 1 including those whose prespecified physician’s choice was ARPI or docetaxel (Table). The confirmed ORR (95% CI) of rucaparib vs physician’s choice for ECOG 0 was 54% (37%–69%) vs 16% (3%–40%); the ORR for ECOG 1 was 37% (22%–53%) vs 18% (5%–40%), respectively. Median OS was similar between arms for rucaparib or physician’s choice; median OS was 23.7 vs 21.7 months (HR, 0.91 [95% CI, 0.61–1.37]) for ECOG 0 and 21.8 vs 20.4 months (HR, 0.85 [95% CI, 0.58–1.24]) for ECOG 1. Conclusions: Rucaparib improved rPFS and ORR in pts with BRCA-mutated prostate cancer with an ECOG PS of 0 or 1. OS was similar for these groups in both arms. These data support rucaparib as a treatment option for pts with BRCA-mutated mCRPC, whether ECOG 0 or 1. Clinical trial information: NCT02975934 . Median rPFS in patients in the ECOG 0 and ECOG 1 groups. Rucaparib, n Physician’s choice, n rPFS Rucaparib, median months rPFS Physician’s choice, median months HR (95% CI) rPFS, ECOG 0 97 50 11.4 8.2 0.48 (0.30–0.76) rPFS, ECOG 1 104 51 10.9 6.1 0.48 (0.31–0.74) rPFS, physician’s choice ARPI, ECOG 0 51 24 11.2 5.6 0.42 (0.22–0.78) rPFS, physician’s choice docetaxel, ECOG 0 46 26 11.5 8.8 0.49 (0.24–0.98) rPFS, physician’s choice ARPI, ECOG 1 52 17 11.2 4.5 0.33 (0.16–0.68) rPFS, physician’s choice docetaxel, ECOG 1 52 34 10.7 7.1 0.59 (0.34–1.01)
Sprains, Strains and Growing Pains: Managing Cognitive Bias to Facilitate Timely Diagnosis in Pediatric Sports Medicine
Scott, Parker, Sim, Leslie , Soma, David , Madsen, Bo E., Thorsteinsdottir, Bjorg , Thorsteinsdottir, Bjoerg , Sim, Leslie A

Mayo Clinic

Children | June 16, 2025 | Volume: 12 | Issue: 6 | Pages: 784

10.3390/children12060784 | PMID 40564742 Get It

Background: Diagnostic delay and error represent pervasive problems in healthcare with grave implications for treatment and prognosis. Though characteristic of human cognition, cognitive biases commonly contribute to delays in the physician decision-making process, particularly in atypical or complex presentations in youth. Methods: We present a case series of three adolescent athletes with varied clinical presentations whose diagnostic conceptualization and treatment were delayed in part due to cognitive biases with consequences for overall health and development, as well as return to sport. Results: The first case depicts how an atypical presentation of celiac disease was attributed to growing pains, illustrating the contribution of anchoring bias and confirmation bias in medical decision making. The second case represents the misattribution of chronic exertional compartment syndrome pain to growing pains and post-exercise soreness, highlighting the influence of ascertainment bias on the initial misdiagnosis. The third case describes how a vertebral mass was misdiagnosed as a left shoulder strain from weightlifting, depicting the contribution of anchoring bias and ascertainment bias in medical decision making. Conclusions: Early recognition of cognitive biases, including confirmation bias, anchoring bias, and ascertainment bias, is crucial for improving medical decision making, particularly in cases of rare or atypical presentations, reducing unnecessary diagnostic delays, and setting more realistic patient expectations. Through discussion of these cases, we highlight concrete steps to manage bias to facilitate timely diagnosis within the primary care and sports medicine setting.
Global research aims for the study of cost and value in health professions education: A Delphi study of international experts
Tolsgaard, Martin G. , Nayahangan, Leizl Joy , Cook, David A. , Schalkwyk, Susan van , You, You , van Schalkwyk, Susan , You, Michelle You , Cleland, J , Tolsgaard, Martin , Madsen, Gorm Roager , Brydges, Ryan , Filho, Carvalho , Cleland, Jennifer

Mayo Clinic

Medical Teacher | May 10, 2025 | Volume: 47 | Issue: 11 | Pages: 1752-1760

10.1080/0142159x.2025.2501254 | PMID 40347090 Get It

Characterization of the Cystic Phenotype Associated with Monoallelic ALG8 and ALG9 Pathogenic Variants
Jawaid, Tabinda , Elbarougy, Doaa E. , Lavu, Sravanthi , Buia, Guillaume, Senum, Sarah R. , Olinger, Eric , Yang, Hana , Bublitz, Joshua T., Ma, Jun , Audrézet, Marie‐Pierre , Madsen, Charles D. , Schauer, R., Baker, Tracy A. , Gregory, Adriana , Orr, Sarah , Barroso‐Gil, Miguel , Neatu, Ruxandra , Joli, Giancarlo, Dahl, Neera K. , Kline, Timothy L. , Jouret, François , Steinman, Theodore I., Watnick, Terry , Larson, Nicholas B. , Halbritter, Jan , Harris, Peter C. , Gastel, Maatje D.A. van , Jawaid, Tabinda , Ma, Jun , Audrézet, Marie-Pierre , Madsen, Charles D , Schauer, Rachel S , Baker, Tracy A , Gregory, Adriana V , Orr, Sarah E , Barroso-Gil, Miguel , Neatu, Ruxandra , Dahl, Neera K , Kline, Timothy L , Gillion, Valentine , Jouret, Francois , Torres, Vicente E , Peters, Dorien J M , Gitomer, Berenice Y , Watnick, Terry J , Chebib, Fouad T , Hogan, Marie C , Olson, Janet E , Larson, Nicholas B , Ars, Elisabet , Halbritter, Jan , Demoulin, Nathalie , Torres, Vicente E , Sayer, John A , Cornec-Le Gall, Emilie , Harris, Peter C , Senum, Sarah R , Elbarougy, Doaa E , Buia, Guillaume, McDonnell, Shannon K. , Dahan, Karin , Perrone, Ronald D. , Peters, Dorien J.M. , Coto, Eliécer , Chebib, Fouad T. , Hogan, Marie C. , Olson, Janet E. , Torres, Vicente E. , Gall, Émilie Cornec-Le

Mayo Clinic

Journal of the American Society of Nephrology | February 3, 2025 | Volume: 36 | Issue: 6 | Pages: 1056-1071

10.1681/asn.0000000613 | PMID 39899384 Get It

Key Points Loss-of-function ALG8 and ALG9 variants were enriched in polycystic kidney/liver groups and International Classification of Diseases–coded cystic individuals in population cohorts. The ALG8 and ALG9 kidney phenotypes were usually mild to moderate, and lower eGFR or kidney failure was rare. ALG8 pathogenic variants sometimes resulted in severe polycystic liver disease. Background Autosomal dominant polycystic kidney disease (ADPKD) is a common, inherited nephropathy often resulting in kidney failure. It is genetically heterogeneous; along with the major genes, PKD1 and PKD2 , at least eight others have been suggested. ALG8 pathogenic variants have been associated with autosomal dominant polycystic liver disease and implicated in ADPKD, while ALG9 has been suggested as an ADPKD gene, but details of the phenotypes and penetrance are unclear. Methods We screened >3900 families with cystic kidneys and/or livers using global approaches to detect ALG8 or ALG9 pathogenic variants. In addition, population cohorts with sequence data (Genomics England 100K Genomics Project, UK Biobank, and Mayo Clinic Biobank [MCBB]) were screened for ALG8 / ALG9 pathogenic variants. Results Multicenter screening of individuals with polycystic kidney and/or liver disease identified 51 (1.3%) ALG8 (7 multiplex) and 23 (0.6%) ALG9 (5 multiplex) families—frequencies that were approximately 10× and approximately 24× greater than nonpolycystic kidney disease controls. Analysis of individuals with polycystic kidney disease phenotypes in 100K Genomics Project, UK Biobank, and MCBB identified nine ALG8 (0.39%) and nine ALG9 (0.39%) families, an enriched frequency over controls. Two individuals had PKD1 and ALG8 pathogenic changes. Eighty-nine percent of individuals with ALG8 mutations with imaging in the entire MCBB had kidney cysts (50%, >10 cysts), with greater median kidney and liver cyst numbers than controls. For ALG9, 78% had kidney cysts (27%, >10 cysts). Individuals with ALG8 mutations typically had mild cystic kidneys with limited enlargement. Liver cysts were common (71%), with enlarged livers (>2L) found in 11 of 62 patients, although surgical intervention was rare. The ALG9 kidney phenotype was also of mild cystic kidneys, but enlarged livers were rare; for both genes, CKD or kidney failure were rare. Conclusions ALG8 and ALG9 are defined as cystic kidney/liver genes but with limited penetrance for lower eGFR.